Moorfields Eye Hospital

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

Retrieved on: 
torsdag, maj 23, 2024
Choroid, Patient, Doctor of Philosophy, Wills Eye Hospital, University of Michigan, University, FRCS, KOL, Moorfields Eye Hospital, Cancer, Compass, MB, Webcast

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET.

Key Points: 
  • BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET.
  • To register, click here .
  • Aura's Therapeutic Area Head Ocular Oncology Anthony Daniels, MD will join the KOLs for a panel discussion moderated by Chris Howerton, PhD from LifeSci Advisors.
  • A live question and answer session will follow the formal presentations.

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Retrieved on: 
måndag, maj 6, 2024
Stargardt disease, MB BS, Geographic atrophy, FACS, Royal College of Ophthalmologists, MB, Therapy, Retina, Bachelor of Science, Eye, Research fellow, Macular degeneration, RBP4, Moorfields Eye Hospital, ARVO

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a Key Opinion Leader Webinar hosted by Jennifer Kim, Director, Equity Research, of Cantor Fitzgerald on Monday, May 13, 2024, at 2:00 p.m. ET.

Key Points: 
  • Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m.
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (University College London Institute of Ophthalmology and Moorfields Eye Hospital), who will discuss an overview of the unmet need for treatments in Stargardt disease (STGD1) and Geographic Atrophy (GA).
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1.
  • A replay of the webinar will be available approximately one week after the event for 90 days under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events .

Eye2Gene and Heidelberg Engineering Announce Collaborative Partnership at ARVO 2024

Retrieved on: 
tisdag, maj 7, 2024
Research, General Health, Optical, Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Genetics, Science, Other Technology, Other Science, Health, Retina, AI, NIHR, Partnership, Artificial intelligence, Similarity, Infrared, OCT, Patient, DSM-IV codes, Data set, Annual general meeting, Medicine, Moorfields Eye Hospital, ARVO, Deep learning

Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.

Key Points: 
  • Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.
  • By combining Eye2Gene's cutting-edge artificial intelligence algorithm with Heidelberg Engineering image quality and innovative workflow solutions, the partnership aims to revolutionize the care pathway for patients with inherited retinal disease.
  • At ARVO 2024, attendees can experience firsthand the power of this collaboration at Stand #1905 and learn more about the collaborative partnership between Eye2Gene and Heidelberg Engineering.
  • "Because inherited diseases are rare, they are challenging to diagnose for most non-specialists," said Nikolas Pontikos, lead researcher for Eye2Gene.

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
onsdag, maj 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Retrieved on: 
tisdag, april 2, 2024
Patient, MIB, ARI, Therapy, AAO, Research, Surgeon, Thomas Jefferson University, German Research Foundation, Chairperson, American Diabetes Association, Macular degeneration, SAB, FACS, Food, Cornell University, Empire, University, Castle Connolly Medical, Laborie (company), Publication, Emerita, AMD, FDA, Cochrane (organisation), Moorfields Eye Hospital, American Academy, Most, Consultant, Physician, Royal college, Diabetic retinopathy, Commander, Pharmaceutical industry

WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901.

Key Points: 
  • “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion.
  • Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad.
  • FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
  • He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
måndag, mars 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
måndag, oktober 2, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Oncology, University of Southern California, Canada, Royal college, Research and development, Central nervous system, University, American Board of Ophthalmology, Retina, Education, Senior, Lysogenic cycle, Cancer, Visual impairment, Record, Life Technologies, AstraZeneca, University of Belgrade, American Board of Commissioners for Foreign Missions, Moorfields Eye Hospital, Novartis, McMaster University, Patient, VDC, RAC, Growth, Immunology, Regulatory affairs, American College, Therapy, Roche, Eye disease, Pharmaceutical industry, Microbiology, Virology, Ophthalmology

“Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.

Key Points: 
  • “Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • “We have built our leadership team with experienced industry leaders who have proven track records of success with multiple drug approvals.
  • Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.
  • Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies.

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Retrieved on: 
måndag, juli 24, 2023
Therapy, Stargardt disease, Principal investigator, RBP4, Geographic atrophy, GA, Moorfields Eye Hospital, Phase 3, HIV disease progression rates, Patient, SAN, Pleasure, Adolescence, United Kingdom, FDA, DRAGON, Safety, Pharmaceutical industry, PHOENIX

Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.

Key Points: 
  • Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.
  • “Completing enrollment of all 90 adolescent subjects across 11 countries worldwide in the Phase 3 DRAGON trial marks an important milestone for our late-stage program in STGD1.
  • Topline data for Tinlarebant in the Phase 2 STGD1 study is expected in the fourth quarter of 2023 and the interim data for the Phase 3 DRAGON trial is expected by mid-2024.
  • In addition, Belite plans to have the first patient enrolled in the 2-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy (GA) in the third quarter of 2023.

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Retrieved on: 
tisdag, juli 18, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, General Health, Health, Consumer, Clinical Trials, Glaucoma, Abstract, ARVO, Li Ka Shing Faculty of Medicine, NR, Eye, Control, NAD, UCL Institute of Ophthalmology, Research, ChromaDex, Trial of the century, School of Clinical Medicine, University of Cambridge, Medicine, Moorfields Eye Hospital, Patient, Peripheral vision, Randomness, School, Investigative Ophthalmology & Visual Science, Optic nerve, Association for Research in Vision and Ophthalmology, Regulatory affairs, Medical device, Medical imaging, Ophthalmology

Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.

Key Points: 
  • Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
  • Dr. Garway-Heath’s abstract titled “ Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls ” observed significantly lower cellular NAD+ levels and impaired mitochondrial function in patients with primary open-angle glaucoma (POAG).
  • Further, higher NAD+ levels were strongly associated with higher mitochondrial function parameters, suggesting increased NAD+ levels are associated with improved energy production and cellular activity.
  • POAG is a condition where pressure builds inside the eye, causing damage to the optic nerve and gradual vision loss.

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Retrieved on: 
onsdag, juli 12, 2023
Biotechnology, Health, Science, Research, Optical, University, Therapy, AMD, Sofinnova, Eye, Paratriathlon, Cell, Doctor of Philosophy, ARCH Venture Partners, Regenerative medicine, Moorfields Eye Hospital, Patient, University of Washington Department of Bioengineering, Vision Institute, Capital, FDA, Patient capital, Pharmaceutical industry, Management, Ophthalmology, MD

F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.

Key Points: 
  • F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
  • Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
  • “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
  • Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor.